Antibe Therapeutics Pauses Otenaproxesul Trial After Exceeding Safety Threshold

Antibe Therapeutics Inc. (TSX: ATE) shared today that it is putting on pause the absorption, metabolism, and excretion study of its osteoarthritis pain treatment lead candidate otenaproxesul. This follows after the clinical study exceeded the pre-specified safety threshold.

The study is part of the drug candidate’s Phase III trial involving 42 subjects. Three of the subjects who were administered 100mg of otenaproxesul exhibited liver transaminase elevations exceeding five times the upper limit. The company, however, noted that other indicators of liver function for these subjects were normal.

These elevations were discovered during the 14-day in-clinic post-administration observation period for subjects who have completed the full drug administration period. Antibe relayed that these observations were unexpected based on the efficacy, safety, and pharmacokinetic studies previously conducted on the drug.

The firm said it plans to discuss the status of the paused study and its outlook with Health Canada.

Antibe Therapeutics last traded at $3.39 on the TSX.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Gold Is Screaming Higher While Currencies Burn | Simon Ridgway – Rackla Metals

We Have the Highest-Grade Antimony Deposit in North America!? | Jim Atkinson -Antimony Resources

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Antibe Therapeutics Proposes Share Consolidation To Enable Potential Nasdaq Listing

It appears that Antibe Therapeutics (TSXV: ATE) is still mulling a share consolidation that it...

Wednesday, July 15, 2020, 10:04:38 PM

Antibe: Canaccord Cuts Price Target From $5.00 To $1.20 After Drug Pivot

In early August, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Monday, October 18, 2021, 11:31:00 AM

Antibe: Canaccord Raises Price Target After Q4 Results

On June 28th, Antibe Therapeutics (TSX: ATE) reported their fourth quarter and year-end financials. The...

Friday, July 2, 2021, 12:18:00 PM

Canaccord Drops Antibe’s Price Target To $0.70 Following Asset Sale

Antibe Therapeutics Inc. (TSX: ATE) recently reported their full-year 2022 results, wherein the company reported...

Friday, July 15, 2022, 02:25:00 PM

Antibe Therapeutics: Canaccord Initiates Coverage, Issues $1.50 Price Target

Recently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company...

Tuesday, August 18, 2020, 01:46:28 PM